What is Chelidonine, and what can it be used for?
Chelidonine, also named ranunculine, is a benzophenanthridine alkaloid isolated from the whole plant of Chelidonium majus. L. It has been used as a painkiller in clinical treatment based on its morphi
Dec 16，2019 Antipyretic analgesics
Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide - reaction / application on synthetic works
Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide is an organic photoinitiator. It is also an important organic intermediate to synthetize polymerization initiators in the area of materials science, mis
Dec 13，2019 Organic reagents
N-phenylpiperidin-4-amine dihydrochloride- reaction / application on synthetic works
N-phenylpiperidin-4-amine dihydrochloride is an important organic intermediate to synthetize substituted phenylpiperidin products.
Dec 13，2019 Organic Chemistry
Dabrafenib Mesylate(GSK-2118436B)- Pharmacodynamics & Bioactivity
Dabrafenib Mesylate is a salt form of Dabrafenib. Dabrafenib is an inhibitor of certain mutated forms of BRAF kinase, several of which may be associated with stimulating tumour growth.
Dec 13，2019 Inhibitors
Cabozantinib (XL184)- antitumour effects
Cabozantinib is a small molecule inhibitor of multiple tyrosine kinase receptors. In vitro, it has demonstrated inhibitory activity against RET, MET and VEGFR-2 and against the RET mutant M918T.
Dec 13，2019 Antineoplastic agents
MDV-3100 (Enzalutamide)- Pharmacodynamic Properties
MDV3100, known as Enzalutamide, is a second-generation androgen receptor (AR) signaling inhibitor. It is able to inhibit binding of androgens to the AR, AR nuclear translocation, and the association o
Dec 13，2019 Inhibitors
Dabigatran etexilate (BIBR-1048)- Pharmacology
Dabigatran etexilate (Pradaxa, BIBR 1048, Boehringer Ingelheim) is the prodrug of dabigatran (originally known as BIBR 953), a potent, nonpeptidic small molecule.
Dec 13，2019 Inhibitors
Larotrectinib (LOXO-101)- Pharmacodynamics
Larotrectinib (VITRAKVIR) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG.
Dec 13，2019 Inhibitors
AZD3759- preclinical and clinical studies
AZD3759 is a selective EGFR inhibitor that can fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue.
Dec 13，2019 Inhibitors
Neratinib- pharmacology
Neratinib is an oral pan HER inhibitor that irreversibly inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2, and HER4.
Dec 13，2019 Inhibitors